Merrill maintains Martek at sell

Martek Biosciences Corp. was reiterated at sell by Merrill Lynch analyst David W. Munno after the company announced yogurt with Martek's DHA is now available in Spain. Merrill found the timing of the announcement suspect since the news is five months old and, presumably, Martek collected revenues in the third quarter from the deal. Further, Merrill said revenue is unlikely to pass $1 million. Shares of the Columbia, Md.-based biotechnology company were up $0.75, or 2.48%, at $31.00 on volume of 359,788 shares versus the three-month running average of 859,714 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.